Lack of hepatic stimulator substance expression promotes hepatocellular carcinoma metastasis partly through ERK-activated epithelial-mesenchymal transition

Laboratory Investigation; a Journal of Technical Methods and Pathology
Xiao-Wei JiaWei An

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies due to its high frequency of metastasis via the epithelial-mesenchymal transition (EMT) pathway. Hepatic stimulator substance (HSS) can protect hepatocytes from injury and promote liver growth. Recent studies indicated that HSS expression is increased in HCC tissues; however, whether HSS expression is potentially associated with HCC metastasis, particularly through the EMT pathway, remains largely unknown. In this study, the relationship between HSS expression and HCC metastasis was investigated in clinical samples of HCC. Meanwhile, the regulation of HCC metastasis and EMT progression by HSS were also analyzed in both in vitro and in vivo models. The results showed that the expression of 23 kDa HSS was significantly decreased among HCC tissues with angioinvasion. A decrease in HSS predicted poor prognosis with a lower survival rate. Furthermore, the growth of xenograft tumors after inoculating MHCC97H-HSS-shRNA (HCC) cells into nude mice was notably accelerated compared to those inoculated with HSS-expressing cells. Further analysis revealed that knockdown of HSS expression in both MHCC97H and HepG2 cells could enhance the migration of these HCC cells. Concu...Continue Reading

References

May 1, 1991·Digestive Diseases and Sciences·D R LaBrecque
Feb 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W E Fleig, G Hoss
Jan 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D R LaBrecqueJ Barton
Sep 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A FrancavillaT E Starzl
Apr 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C R GandhiT E Starzl
Nov 16, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Chengrong LuFuchu He
Mar 22, 2002·The Lancet Oncology·D M Parkin
Aug 22, 2002·Nature Reviews. Cancer·Jean Paul Thiery
Apr 30, 2003·Protein Science : a Publication of the Protein Society·Chia-Kuei WuJohn P Rose
Jul 29, 2003·Toxicological Sciences : an Official Journal of the Society of Toxicology·Francoise de LonguevilleMickael Canning
Sep 6, 2003·Liver International : Official Journal of the International Association for the Study of the Liver·Alexandra P MargeliStamatios E Theocharis
Jun 29, 2005·Development·Alejandro Barrallo-Gimeno, M Angela Nieto
Aug 16, 2005·Current Opinion in Cell Biology·Margit A HuberHartmut Beug
Sep 16, 2005·The New England Journal of Medicine·Jiang HePaul K Whelton
Aug 25, 2006·Nature Reviews. Cancer·Paraskevi A Farazi, Ronald A DePinho
Feb 15, 2008·Journal of Hepatology·Chinnasamy ThirunavukkarasuChandrashekhar R Gandhi
Oct 31, 2008·Advances in Therapy·Patricia Roxburgh, T R Jeffry Evans
Dec 17, 2008·Digestive Diseases and Sciences·Georgios GribilasStamatios E Theocharis
Mar 26, 2010·The Journal of Clinical Investigation·Janice Jou, Anna Mae Diehl
Nov 27, 2010·Biochemical and Biophysical Research Communications·Maren IlowskiWolfgang E Thasler
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Aug 7, 2013·The International Journal of Biochemistry & Cell Biology·Lorenzo PolimenoAntonio Francavilla
Aug 10, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lulu LiuXin-Yuan Guan
Oct 26, 2013·American Journal of Physiology. Gastrointestinal and Liver Physiology·Guanhua Xie, Anna Mae Diehl
Dec 7, 2013·The International Journal of Biochemistry & Cell Biology·Haifeng ZhangWei An
Jun 1, 2014·The International Journal of Biochemistry & Cell Biology·Antonio FrancavillaLorenzo Polimeno
Oct 13, 2014·Molecular Oncology·Viola BigattoCarla Boccaccio

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
electrophoresis
transfection
xenograft

Software Mentioned

SPSS
Image J

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.